AEON Stock Overview
A clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
AEON Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.99 |
| 52 Week High | US$17.17 |
| 52 Week Low | US$1.38 |
| Beta | 0.76 |
| 1 Month Change | -57.84% |
| 3 Month Change | -80.96% |
| 1 Year Change | -80.77% |
| 3 Year Change | -79.53% |
| 5 Year Change | n/a |
| Change since IPO | -79.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| AEON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 25.9% | 0.7% | 1.2% |
| 1Y | -80.8% | 5.0% | 27.7% |
Return vs Industry: AEON underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: AEON underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| AEON volatility | |
|---|---|
| AEON Average Weekly Movement | 25.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: AEON's share price has been volatile over the past 3 months.
Volatility Over Time: AEON's weekly volatility has increased from 20% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 10 | Marc Forth | www.aeonbiopharma.com |
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
AEON Biopharma, Inc. Fundamentals Summary
| AEON fundamental statistics | |
|---|---|
| Market cap | US$63.99m |
| Earnings (TTM) | -US$137.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs AEON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AEON income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$137.01m |
| Earnings | -US$137.01m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -2.6% |
How did AEON perform over the long term?
See historical performance and comparison